Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures Triathlon Medical Ventures Triathlon Medical Ventures
Triathlon Medical Ventures - Homepage
Triathlon Medical Ventures - Team
Triathlon Medical Ventures - Investment Focus
Triathlon Medical Ventures - Investment Strategy
Triathlon Medical Ventures - Investment Criteria
Contact Triathlon Medical Ventures - Evaluation Process
Triathlon Medical Ventures - Portfolio
Triathlon Medical Ventures - News
Triathlon Medical Ventures - Links
Contact Contact Triathlon Medical Ventures

Triathlon Medical Ventures

 

 

 

 

 


Whether you're an entrepreneur or a venture capitalist, you'll find a warm welcome at Triathlon Medical Ventures. Prior to opening our doors in 2004, Triathlon's team has been investing in life science business opportunities for more than fifteen years. And we are also industry veterans, experienced at growing medical device and biotechnology companies from the inside out - as owners, directors and operational managers.

Triathlon Medical Ventures is a Midwest-based venture capital firm that invests exclusively in the life sciences. We provide equity capital to early and expansion stage companies with proprietary biomedical technology platforms or products addressing significant human healthcare needs.

We are geographically focused on early stage opportunities in the Midwest but will also invest in later stage companies nationwide. We are headquartered in Cincinnati, with offices and partners in Indianapolis and Louisville. The partners are industry veterans with extensive experience as both operational managers and venture capitalists.

We invite you now to explore these web pages and consider how Triathlon Medical Ventures might be the right partner for your investment opportunity.



RECENT NEWS

Click here for Triathlon Medical Ventures related videos on YouTube

May 12, 2014
Akebia to Present at the Annual UBS Global Healthcare Conference

May 12, 2014
Akebia Announces First Quarter 2014 Financial Results and Recent Corporate Highlights

May 12, 2014
New FLXfit 3D Cage to be presented at ISASS

May 12, 2014
Expanding Orthopedics’ Cage Presented at ISASS

May 6, 2014
CoLucid Pharmaceuticals, Inc., Announces Agreement from the FDA on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Lasmiditan in Migraine Including Patients with Risk Factors of Cardiovascular Disease

May 6, 2014
Juventas Therapeutics to Present Top-Line Interim Results from Phase II STOP-HF Trial in Late-Breaking Oral Presentation at European Society of Cardiology Heart Failure Congress

May 5, 2014
Aerpio Therapeutics Presents Full Results from Phase 1b/2a Study of AKB-9778

May 2, 2014
Endocyte Reports First Quarter Financial Results and Provides Clinical Update

May 2, 2014
Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis

April 23, 2014
Aerpio Therapeutics Closes $22M Financing

April 15, 2014
Akebia Therapeutics Announces Completion of Enrollment in its Phase 2b Clinical Study of AKB-6548

April 8, 2014
Mitralign Completes Enrollment in EU Study for its Novel Catheter-based Valve Repair Device

April 7, 2014
Aerpio Therapeutics to Present at Needham Healthcare Conference

March 26, 2014
Akebia Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

March 25, 2014
Endocyte, Inc. Announces Proposed Offering of Common Stock

March 21, 2014
Endocyte Announces Phase 2b TARGET Trial Results Evaluating Vintafolide/Docetaxel Combination in Non-Small Cell Lung Cancer (NSCLC) Met the Primary Endpoint of Improved Progression Free Survival

March 21, 2014
Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer

March 20, 2014
Akebia Therapeutics Announces Pricing of Initial Public Offering

February 13, 2014
Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema

February 4, 2014
Juventas Therapeutics initiates Phase II RETRO-HF clinical trial enrollment for patients with heart failure

December 3, 2013
Experienced Drug Development and Partnering CEO Takes the Helm at Tolera

November 4, 2013
Tolera Therapeutics announces agreement with the FDA on a Special Protocol Assessment for planned Phase 3 clinical trial of TOL101 in prophylaxis of acute renal rejection

October 28, 2013
Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure

October 22, 2013
CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine

October 17, 2013
Over 2000 XPED Screws Implanted

October 3, 2013
Kent Oyler: George Emont was the quiet giant of Louisville’s entrepreneurial community (Link)

June 4, 2013
Akebia Closes $41 Million Series C

 
 
Copyright © 2004 - Triathlon Medical Ventures - All Rights Reserved Web Site Credits Legal Notices & Privacy Policy